Really sharp analysis on the daughter nuclide constraint. The miniprotein angle is clever because it solves the Bi-213 kidney toxicity through rapid tumor delivery rather than just trying to engineer better chelators. I've seen simialr issues with longer half-life conjugates in radioimmunotherapy trials, where systemic exposure becomes the limiting factor. The skepticism around TNBC applicability feels spot on given that 62% vs 90% target expresion gap.
Really sharp analysis on the daughter nuclide constraint. The miniprotein angle is clever because it solves the Bi-213 kidney toxicity through rapid tumor delivery rather than just trying to engineer better chelators. I've seen simialr issues with longer half-life conjugates in radioimmunotherapy trials, where systemic exposure becomes the limiting factor. The skepticism around TNBC applicability feels spot on given that 62% vs 90% target expresion gap.
Appreciate you reading!